DEERFIELD (dpa-AFX) - Baxter International (BAX) announced new data showing
expanded hemodialysis, known as HDx therapy, enabled by Theranova dialyzer, was
associated with an approximately 25% lower all-cause mortality risk for up to
four years when compared to high-flux hemodialysis. The new data is from a
48-month observational cohort study involving 1,092 dialysis patients at 11
Baxter Renal Care Services Centers in Colombia.

'It is very exciting to see the results of this four-year study, indicating
approximately 25% lower mortality for chronic kidney patients with the use of
Baxter's Theranova dialyzer,' said Peter Rutherford, vice president, Medical
Affairs, Kidney Care, Baxter.

For More Such Health News, visit rttnews.com.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX